Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Shanghai Henlius Biotech

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Henlius Adalimumab Biosimilar Approved by NMPA

              Contact the Supplier

              Lead Product(s): Adalimumab

              Therapeutic Area: Immunology Product Name: HLX03

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2020

              Details:

              Adalimumab is the third monoclonal antibody developed by Henlius and approved in China, after the Company's rituximab biosimilar HLX01, and trastuzumab biosimilar HLX02, the first China-developed mAb biosimilar approved both in China and in the EU.

              Innovent Biologics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Innovent’s Product SULINNO’s New Indication Approved by NMPA China, For Patients with Polyarticular Juvenile Idiopathic Arthritis

              Contact the Supplier

              Lead Product(s): Adalimumab

              Therapeutic Area: Immunology Product Name: Sulinno

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 23, 2020

              Details:

              SULINNO® (adalimumab injection) is a recombinant human anti-TNF-α monoclonal antibody drug approved by the china NMPA for the treatment of polyarticular juvenile idiopathic arthritis (pJIA). This is the fourth approved indication of SULINNO® in China.

              Innovent Biologics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China

              Contact the Supplier

              Lead Product(s): Adalimumab

              Therapeutic Area: Immunology Product Name: Sulinno

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 03, 2020

              Details:

              SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in China.

              PharmaCompass__DigitalAd